Bavarian Nordic Drops Cancer Vaccine Work

Denmark-based Bavarian Nordic announced that it will halt development of its cancer vaccine, TAEK-VAC, which was designed to target two proteins—HER2 and brachyury. The company said that the vaccine “has reached a stage where clinical expansion and further investments would be required” and that it would “focus its future R&D efforts on infectious diseases” instead. A phase I trial has been assessing the vaccine in patients with chordoma, HER2-positive breast cancer, or HER2-positive gastric/gastroesophageal junction cancers.